Recursion Pharmaceuticals, Inc. (RXRX)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Research and Development Agreements Revenue	67.01M	74.26M	58.49M
Grant Revenue	1.22M	425.00K	351.00K
Revenue (Other)	1.00K	-	-
Revenue (Total)	68.23M	74.68M	58.84M

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
United States Revenue	-	39.34M	57.38M
United Kingdom Revenue	-	35.34M	1.14M
Other Geographic Revenue	-	-	327.00K
Revenue (Total)	68.23M	74.68M	58.84M

Data Source: Fiscal.ai Last updated: Nov 2, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 3, 2026

Data Sources Report a data error